An Open-Label, Dose-Escalation, Safety Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

  • sponsor
    Incyte Europe Sàrl
Updated on 8 December 2020
solid tumors
solid tumor
advanced solid tumor


An Open-Label, Dose-Escalation, Safety Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors


This purpose of this study is to explore the safety of INCAGN01876 in subjects with advanced or metastatic solid tumors. The study has 2 parts: Part 1 will determine the recommended dose of INCAGN01876, while Part 2 will further evaluate the recommended dose in subjects with certain tumor types (endometrial cancer, melanoma, non-small cell lung cancer, and renal cell carcinoma).

For more information, please contact Incyte Corporation (responsible party for Incyte Europe Sàrl) at +1 (855) 463-3463.

Condition All Solid Tumors, Solid Tumors
Clinical Study IdentifierTX149864
SponsorIncyte Europe Sàrl
Last Modified on8 December 2020


Yes No Not Sure

Inclusion Criteria

Locally advanced or metastatic disease that must not be amenable to resection with curative intent
Part 1 subjects who have advanced or metastatic solid tumors, Part 2 subjects who have advanced or metastatic endometrial cancer, melanoma, non-small cell lung cancer, or renal cell carcinoma
Disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or subjects who refuse standard treatment
Measurable disease based on current treatment response criteria (RECIST v1.1)
Daily performance status of 0 to 1 based on the Eastern Cooperative Oncology Group (ECOG) ratings

Exclusion Criteria

Laboratory and medical history parameters not within the protocol-defined range
Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug
Has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy
Receipt of a live vaccine within 30 days of planned start of study therapy
Active autoimmune disease that required systemic treatment in the past 2 years
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note